Figure 2.

Blockage of PD-1/PDL-1 pathway by anti-PD-1/PDL-1: PD-1 expressed on the activated T cells. The receptor-ligand interaction induces an inhibitory antitumor activity. Whereas the administration of anti-PD1 counter the inhibitory anti-tumor response and unleash the T-cell activity by upregulating the T-cell activation and proliferation by enhancing effector function and subsequent tumor cell death